伐尼克兰减少心梗后室性早搏的随机2期研究
这项多中心随机双盲安慰剂对照2期试验纳入118例心梗后频发室性早搏(PVCs≥1000次/24h)患者,在指南指导药物治疗基础上加用伐尼克兰0.5mg每日两次或安慰剂共45天。伐尼克兰组24小时PVC负荷降幅比安慰剂多60.1个百分点(95%CI:21.3–98.8个百分点;P=0.001),应答率更高(67.8% vs 30.5%),非持续性室速发生率更低(20.3% vs 37.3%),且未见致心律失常证据。
要点
- 伐尼克兰组PVC负荷降幅比安慰剂多60.1个百分点,应答率达67.8%。
- 非持续性VT发生率伐尼克兰组20.3%显著低于安慰剂组37.3%。
- 伐尼克兰组无死亡或恶性室性心律失常,不良事件发生率与安慰剂相当。
核心结论
- 在心梗后频发PVC患者中,伐尼克兰较安慰剂显著降低PVC负荷和非持续性VT发生率,未发现致心律失常效应,支持心脏nAChR作为抗心律失常新靶点。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、概念验证2期试验(Var-PVC;NCT06780215)。
- 纳入118例心梗≥4周后且72小时动态心电图PVCs≥1000次/24h的成人,1:1随机分配至伐尼克兰0.5mg bid或安慰剂共45天,均联用指南指导药物治疗。
主要发现
- 主要终点:伐尼克兰组24小时PVC计数降幅比安慰剂多60.1个百分点(95%CI:21.3–98.8个百分点;P=0.001)。
- 关键次要终点:应答率伐尼克兰组67.8% vs 安慰剂组30.5%(RR:2.22;95%CI:1.46–3.39;P<0.0001)。
- 非持续性VT发生率伐尼克兰组20.3% vs 安慰剂组37.3%(RR:0.49;95%CI:0.29–0.85;P=0.007)。
- 伐尼克兰组无死亡或恶性室性心律失常发生,不良事件发生率与安慰剂组相当。
关键数值与推荐
- 入选标准:心梗后≥4周,72小时动态心电图PVCs≥1000次/24h。
- 干预方案:伐尼克兰0.5mg bid或匹配安慰剂,疗程45天,联用指南指导药物治疗。
临床怎么用
- 心梗后频发PVC患者可考虑伐尼克兰作为非离子通道类抗心律失常选择,但目前仍需更大规模结局驱动试验验证。
- 该方案在当前阶段仍限于临床研究范畴,常规临床应用尚缺乏硬终点证据。
局限性
- 探索性概念验证2期试验,样本量有限(118例),未设置硬终点。
- 短期随访(6周),长期安全性与心血管结局获益尚未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional antiarrhythmic drugs that target cardiac ion channels carry proarrhythmic risks, highlighting the need for alternative therapeutic approaches. Cardiac nicotinic acetylcholine receptors (nAChRs) represent a novel electrophysiological target. OBJECTIVES: The aim of this exploratory, proof-of-concept phase 2 trial was to evaluate the effect of varenicline, a partial nAChR agonist, on frequent premature ventricular complexes (PVCs) after myocardial infarction (MI) and to assess its short-term safety and biological target engagement. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, adults with frequent PVCs (≥1,000/24 h) assessed using 72-hour ambulatory electrocardiographic monitoring at ≥4 weeks post-MI were randomly assigned (1:1) to varenicline 0.5 mg twice daily or matching placebo for 45 days, in addition to guideline-directed medical therapy. The primary endpoint was the percentage change in 24-hour PVC count from baseline to week 6. Key secondary endpoints included responder rate (≥50% reduction in PVC count) and the incidence of nonsustained ventricular tachycardia (VT). RESULTS: Among 118 randomized patients, varenicline produced a 60.1 percentage point greater reduction in PVC burden compared with placebo (95% CI: 21.3-98.8 percentage points; P = 0.001). The responder rate was higher with varenicline (67.8% vs 30.5%; RR: 2.22; 95% CI: 1.46-3.39; P < 0.0001), and nonsustained VT incidence was lower (20.3% vs 37.3%; RR: 0.49; 95% CI: 0.29-0.85; P = 0.007). No deaths or malignant ventricular arrhythmias occurred in the varenicline group, with comparable adverse event rates between groups. CONCLUSIONS: In this phase 2 trial, varenicline significantly reduced PVC burden and nonsustained VT incidence in post-MI patients without evidence of a proarrhythmic effects. These findings support cardiac nAChRs as a potential antiarrhythmic target and justify further evaluation in larger outcome-driven trials. (Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial [Var-PVC]; NCT06780215).
引用
- Shen, Guo, Zeng, et al. Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study. J Am Coll Cardiol. 2026. PMID: 41778949. doi:10.1016/j.jacc.2025.12.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。